Skip to content

Journey Medical Corporation DERM Gain From Partial Loss Recovery In Wire Fraud

Gain From Partial Loss Recovery In Wire Fraud at other companies

Matthews International logo
Matthews InternationalMATW
$538K
Atlas Energy Solutions logo
Atlas Energy SolutionsAESI
-$3.33M
Orion logo
OrionOEC
-$1.73M-112%
ResMed logo
ResMedRMD
$0
Pebblebrook Hotel Trust logo
Pebblebrook Hotel TrustPEB
$0-100%
PRA Group logo
PRA GroupPRAA
$287.59M+8.5%

Other financials

Income statement

See full
Revenue$16.0M+21.5%
Gross profit$9.7M+16.7%
Operating income-$1.5M+55.1%
Net income-$2.2M+45.2%
EPS (diluted)-$0.08+55.6%

Balance sheet

See full
Cash & equivalents$27.2M+29.2%
Total debt$25.5M+1.2%
Total equity$30.8M+43.1%
Total assets$91.5M+7.7%

Cash flow

See full
Operating cash flow$2.9M+203%
CapEx$3.8M
Free cash flow-$6.0M

Valuation

See full
Market cap$194.94M+20.9%
Enterprise value$193.19M+16.2%
P/S+0.2×

Profitability

See full
Gross margin65.4%-1.0pp
Operating margin-9.8%
Net margin-14.8%
FCF margin-43%

Returns & leverage

See full
Return on equity-36.6%
Debt / equity0.8×-0.3×
Current ratio1.7×+0.4×

Where this comes from

Reported directly by Journey Medical Corporation in its filing.

Tagged under the XBRL concept derm:GainFromPartialLossRecoveryInWireFraud.

The official record: Journey Medical Corporation’s 10-K, filed March 26, 2026, on SEC EDGAR. View the filing →

Ask your AI about Journey Medical Corporation's gain from partial loss recovery in wire fraud.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Journey Medical Corporation's gain from partial loss recovery in wire fraud?
Journey Medical Corporation (DERM) reported gain from partial loss recovery in wire fraud of $1.14M in Q4 2024.
What does gain from partial loss recovery in wire fraud mean?
This metric represents the recovery of funds previously lost due to fraudulent wire activity. It reflects non-recurring inflows that offset prior operational losses, providing insight into the effectiveness of recovery efforts and internal control remediation. Investors should treat this as a one-time adjustment that does not reflect core pharmaceutical commercialization performance.